Merganser Biotech Inc. Appoints Remy Sukhija As Chief Operating Officer

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Merganser Biotech Inc. ("Merganser"), a preclinical stage biotech company focused on the development of hepcidin mimetic peptides for the treatment of rare hematology and iron overload diseases, announced today that Remy Sukhija has been appointed to the role of Chief Operating Officer, effective immediately.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.